| In partnership with |  |
| & The Option Pit | Good day, 360! | Here are some of our top movers today. "Trade the Fed" LIVE today with Jeff Bishop & Jason Bond @2pm EST→ must be in Mission to Million to take part. Super sale ends today🔥. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | BDRX - Up over 45% in the pre-market after announcing it is on track to initiate its funded Phase 3 trial in FAP next quarter | XHLD - Up over 40% in pre after announcing $1million stock repurchase program yesterday | BDTX - Up over 29% in pre after announcing a global licensing agreement with Servier for BDTX-4933, a targeted oncology therapy | | *sponsored by Blossom Social | 📚 Join the Duolingo for Investing | | 📈 Want to learn the fundamentals of investing? Check out the app Blossom where you can find over 50 hours of Duolingo-style lessons with videos and quizzes, taught by some of North America's largest investing content creators. Courses like: | | ⭐️ With a 4.7 rating in the App Store and ranked an Essential Finance App of 2024 by Apple, Blossom is loved by over 250,000 members. | 🤗 On top of the educational courses, Blossom is also a social network and community for investors where you can learn and get investing ideas from the community - all backed up by what people are actually investing in. | 🌼 Join Blossom for free! 🌼 |
|
| HOTLIST🔥 | BDRX - Up over 45% in the pre-market after announcing it is on track to initiate its funded Phase 3 trial in FAP next quarter | Biodexa Pharmaceuticals Plc (BDRX) is a clinical stage biopharmaceutical company that focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. | In the pre-market this morning, the company announced it is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). | In just the last few weeks, Biodexa received Fast Track designation from the FDA, conducted a successful Type C (pre-Phase 3 protocol finalization) meeting with the FDA and appointed a clinical research organization (CRO) to conduct the European component of its registrational Phase 3 trial. A CRO for the U.S. component was appointed earlier. | Shares of BDRX traded up over 45% in the pre-market in reaction to the update. | | The first target for bulls is the pre-market high at $3.32. | Beyond that, $3.50, $4, $4.20, $4.75 and $5.05 come into play. | Below $3.32, targets to the downside are $3, $2.80, $2.40, $2.25 and then a gap fill at $2.02. | | XHLD - Up over 40% in pre after announcing $1million stock repurchase program yesterday | TEN Holdings Inc. (XHLD) provides event, production, and broadcasting services in the United States. The company organize virtual, hybrid, and physical events for conferences, marketing events, product launches, training, and investor and shareholder meetings. | Yesterday after-noon, the company announced that its board of directors (the "Board of Directors") has authorized a stock repurchase program, effective March 17, 2025. Under the program, the Company may, from time to time, repurchase up to $1 million worth of its outstanding shares of common stock with an evergreen term. | After closing yesterday up over 17%, XHLD traded up over 40% in the pre-market this morning in reaction to the news. | | The $0.7411 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $0.80, $0.85, $0.90 and then the pre-market high at $0.95. Beyond that, $1, $1.10, $1.20, $1.30 and $1.38 come into play. | Below $0.7411, targets to the downside are $0.70, $0.65, $0.60, $0.55 and then $0.50. | | | | BDTX - Up over 29% in pre after announcing a global licensing agreement with Servier for BDTX-4933, a targeted oncology therapy | Black Diamond Therapeutics Inc. (BDTX) is a clinical-stage oncology medicine company that focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. | In the pre-market this morning, the company announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. | Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors. | Under the terms of the agreement, Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications, including non-small cell lung cancer (NSCLC), with potential applications in other solid tumors. Black Diamond Therapeutics will receive an upfront payment of $70 million and will be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales. | Based on yesterday's closed, BDTX had a market cap of $95 million according to Finviz. | BDTX traded up over 29% in the pre-market in reaction to the news. | | The $2.05 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $2.30 and then the pre-market high at $2.43. Beyond that, $2.60, $2.80, $3 and $3.40 come into play. | Below $2.05, targets to the downside are $1.98, $1.80 and then a gap fill at $1.68. | | MARKET NEWS 📰 | | | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate's sites and it is the affiliate's responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don't spend any money on these products unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar